Literature DB >> 23514290

Colony-stimulating factors for febrile neutropenia during cancer therapy.

Charles L Bennett1, Benjamin Djulbegovic, LeAnn B Norris, James O Armitage.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23514290      PMCID： PMC3947590          DOI： 10.1056/NEJMct1210890

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  41 in total

Review 1.  Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer.

Authors:  Gary H Lyman; Richard L Barron; Jaime L Natoli; Ross M Miller
Journal:  Crit Rev Oncol Hematol       Date:  2011-06-01       Impact factor: 6.312

Review 2.  Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.

Authors:  Wolfgang Jelkmann
Journal:  Am J Hematol       Date:  2010-10       Impact factor: 10.047

3.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

4.  Use of colony-stimulating factors with chemotherapy: opportunities for cost savings and improved outcomes.

Authors:  Arnold L Potosky; Jennifer L Malin; Benjamin Kim; Elizabeth A Chrischilles; Solomon B Makgoeng; Nadia Howlader; Jane C Weeks
Journal:  J Natl Cancer Inst       Date:  2011-06-13       Impact factor: 13.506

5.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Authors:  Nicole M Kuderer; David C Dale; Jeffrey Crawford; Leon E Cosler; Gary H Lyman
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

6.  Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.

Authors:  Roy E Smith; John Bryant; Arthur DeCillis; Stewart Anderson
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

7.  Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.

Authors:  Mary V Relling; James M Boyett; Javier G Blanco; Susana Raimondi; Frederick G Behm; John T Sandlund; Gaston K Rivera; Larry E Kun; William E Evans; Ching-Hon Pui
Journal:  Blood       Date:  2003-01-16       Impact factor: 22.113

Review 8.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

Review 9.  Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis.

Authors:  Katy L Cooper; Jason Madan; Sophie Whyte; Matt D Stevenson; Ron L Akehurst
Journal:  BMC Cancer       Date:  2011-09-23       Impact factor: 4.430

10.  Long-term safety of filgrastim (rhG-CSF) administration.

Authors:  Dennis L Confer; John P Miller
Journal:  Br J Haematol       Date:  2007-04       Impact factor: 6.998
View more
  51 in total

1.  Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.

Authors:  Scott A Strassels; Michael Dickson; Leann B Norris; Charles L Bennett
Journal:  J Natl Cancer Inst       Date:  2013-07-19       Impact factor: 13.506

2.  Management and Preventive Measures for Febrile Neutropenia.

Authors:  Austin J Lucas; Jacqueline L Olin; Megan D Coleman
Journal:  P T       Date:  2018-04

3.  Conversion of danger signals into cytokine signals by hematopoietic stem and progenitor cells for regulation of stress-induced hematopoiesis.

Authors:  Jimmy L Zhao; Chao Ma; Ryan M O'Connell; Arnav Mehta; Race DiLoreto; James R Heath; David Baltimore
Journal:  Cell Stem Cell       Date:  2014-02-20       Impact factor: 24.633

4.  Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.

Authors:  Brian Chen; Sumimasa Nagai; James O Armitage; Bartlett Witherspoon; Chadi Nabhan; Ashley C Godwin; Y Tony Yang; Anuhya Kommalapati; Sri Harsha Tella; Carlo DeAngelis; Dennis W Raisch; Oliver Sartor; William J Hrushesky; Paul S Ray; Paul R Yarnold; Bryan L Love; LeAnn B Norris; Kevin Knopf; Laura Bobolts; Joshua Riente; Stefano Luminari; Robert C Kane; Shamia Hoque; Charles L Bennett
Journal:  Oncologist       Date:  2019-03-06

Review 5.  Emergency granulopoiesis.

Authors:  Markus G Manz; Steffen Boettcher
Journal:  Nat Rev Immunol       Date:  2014-04-22       Impact factor: 53.106

6.  A Phase I study to determine safety, pharmacokinetics, and pharmacodynamics of ANF-RHO™, a novel PEGylated granulocyte colony-stimulating factor, in healthy volunteers.

Authors:  Hemant Misra; John Berryman; Ronald Jubin; Abraham Abuchowski
Journal:  Invest New Drugs       Date:  2017-07-28       Impact factor: 3.850

7.  Secreted protein Del-1 regulates myelopoiesis in the hematopoietic stem cell niche.

Authors:  Ioannis Mitroulis; Lan-Sun Chen; Rashim Pal Singh; Ioannis Kourtzelis; Matina Economopoulou; Tetsuhiro Kajikawa; Maria Troullinaki; Athanasios Ziogas; Klara Ruppova; Kavita Hosur; Tomoki Maekawa; Baomei Wang; Pallavi Subramanian; Torsten Tonn; Panayotis Verginis; Malte von Bonin; Manja Wobus; Martin Bornhäuser; Tatyana Grinenko; Marianna Di Scala; Andres Hidalgo; Ben Wielockx; George Hajishengallis; Triantafyllos Chavakis
Journal:  J Clin Invest       Date:  2017-08-28       Impact factor: 14.808

8.  Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

Authors:  Polina Zjablovskaja; Petr Danek; Miroslava Kardosova; Meritxell Alberich-Jorda
Journal:  J Vis Exp       Date:  2018-02-21       Impact factor: 1.355

9.  Endothelial cells translate pathogen signals into G-CSF-driven emergency granulopoiesis.

Authors:  Steffen Boettcher; Rahel C Gerosa; Ramin Radpour; Judith Bauer; Franziska Ampenberger; Mathias Heikenwalder; Manfred Kopf; Markus G Manz
Journal:  Blood       Date:  2014-07-02       Impact factor: 22.113

10.  Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Seiji Naito
Journal:  Support Care Cancer       Date:  2014-07-05       Impact factor: 3.603
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.